Adial Pharmaceuticals Inc Total Liabilities
Adial Pharmaceuticals Inc total liabilities. Based on the latest financial reports, Adial Pharmaceuticals Inc (ADIL) has total liabilities worth $28.93 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Adial Pharmaceuticals Inc (ADIL) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Adial Pharmaceuticals Inc (2015–2025)
Total liabilities of Adial Pharmaceuticals Inc from 2015 to 2025. This chart illustrates how Adial Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore Adial Pharmaceuticals Inc (ADIL) long-term investment share to see how much of total assets are deployed in long-term investments.
Adial Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Adial Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Advicenne
PA:ALDVI
|
France | €30.73 Million |
|
Antec Inc
TWO:6276
|
Taiwan | NT$380.09 Million |
|
Mlk Foods Public Company Ltd
WAR:MLK
|
Poland | zł154.09 Million |
|
Karnalyte Resources Inc.
TO:KRN
|
Canada | CA$2.79 Million |
|
Admiralty Resources NL
AU:ADY
|
Australia | AU$18.25 Million |
|
Four Leaf Acquisition Corporation Class A Common Stock
NASDAQ:FORL
|
USA | $26.89 Million |
|
Primega Group Holdings Limited
NASDAQ:ZDAI
|
USA | $864.97K |
|
Leyand International Tbk
JK:LAPD
|
Indonesia | Rp152.73 Billion |
Liability Composition Analysis (2015–2025)
This chart breaks down Adial Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Adial Pharmaceuticals Inc balance sheet assets.
Liquidity & Leverage Metrics
Adial Pharmaceuticals Inc Total Liabilities Ratios Explained
Adial Pharmaceuticals Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.63 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 185.47 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.99 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Adial Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Adial Pharmaceuticals Inc (2015–2025)
The table below shows the annual total liabilities of Adial Pharmaceuticals Inc from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $1.52 Million | +55.96% |
| 2024-12-31 | $975.86K | +49.32% |
| 2023-12-31 | $653.51K | -73.39% |
| 2022-12-31 | $2.46 Million | -40.47% |
| 2021-12-31 | $4.13 Million | +174.09% |
| 2020-12-31 | $1.51 Million | +179.26% |
| 2019-12-31 | $539.05K | +108.96% |
| 2018-12-31 | $257.97K | -75.00% |
| 2017-12-31 | $1.03 Million | +304.71% |
| 2016-12-31 | $255.02K | +380.44% |
| 2015-12-31 | $53.08K | -- |
About Adial Pharmaceuticals Inc
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid p… Read more